» Articles » PMID: 26612339

Elucidating the Burden of Recurrent and Chronic Digital Ulcers in Systemic Sclerosis: Long-term Results from the DUO Registry

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2015 Nov 28
PMID 26612339
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Digital ulcers (DUs) occur in up to half of patients with systemic sclerosis (SSc) and may lead to infection, gangrene and amputation with functional disability and reduced quality of life. This study has elucidated the burden of SSc-associated DUs through identification of four patient categories based on the pattern of DU recurrence over a 2-year observation period.

Methods: Patients with SSc-associated DUs enrolled in the Digital Ulcers Outcome Registry between 1 April 2008 and 19 November 2013, and with ≥2 years of observation and ≥3 follow-up visits during the observation period were analysed. Incident DU-associated complications were recorded during follow-up. Work and daily activity impairment were measured using a functional assessment questionnaire completed by patients after the observation period. Potential factors that could predict incident complications were identified in patients with chronic DUs.

Results: From 1459 patients, four DU occurrence categories were identified: 33.2% no-DU; 9.4% episodic; 46.2% recurrent; 11.2% chronic. During the observation period, patients from the chronic category had the highest rate of incident complications, highest work impairment and greatest need for help compared with the other categories. Independent factors associated with incident complications included gastrointestinal manifestations (OR 3.73, p=0.03) and previous soft tissue infection (OR 5.86, p=0.01).

Conclusions: This proposed novel categorisation of patients with SSc-associated DUs based on the occurrence of DUs over time may help to identify patients in the clinic with a heavier DU burden who could benefit from more complex management to improve their functioning and quality of life.

Citing Articles

The predictive value of anti-IFI16 antibodies for the development or persistence of digital ulcers in systemic sclerosis.

Huang L, Chen C, Cheng Y, Wang L, Ye W, Yang H Clin Rheumatol. 2025; 44(2):727-738.

PMID: 39789317 DOI: 10.1007/s10067-024-07296-6.


Platelet-rich plasma for the treatment of scleroderma-associated ulcers: a single-center experience and literature review.

Condorelli A, Paganelli A, Marraccini C, Ficarelli E, Motolese A, Contu L Dermatol Reports. 2024; 16(3):9878.

PMID: 39539989 PMC: 11558311. DOI: 10.4081/dr.2024.9878.


Development of a measuring app for systemic sclerosis-related digital ulceration (SALVE: Scleroderma App for Lesion VErification).

Davison A, Krishan A, New R, Murray A, Dinsdale G, Manning J Rheumatology (Oxford). 2024; 63(12):3297-3305.

PMID: 39029921 PMC: 11637552. DOI: 10.1093/rheumatology/keae371.


Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review.

Ross L, Maltez N, Hughes M, Schoones J, Baron M, Chung L Rheumatology (Oxford). 2023; 62(12):3785-3800.

PMID: 37335850 PMC: 10691932. DOI: 10.1093/rheumatology/kead289.


Prevalence of and factors independently associated with digital ischemic complications in patients with systemic sclerosis.

Guayboon T, Muangchan C J Scleroderma Relat Disord. 2023; 8(1):43-52.

PMID: 36743812 PMC: 9896203. DOI: 10.1177/23971983221118720.


References
1.
Xu D, Li M, Hou Y, Wang Q, Hu C, Song N . Clinical characteristics of systemic sclerosis patients with digital ulcers in China. Clin Exp Rheumatol. 2013; 31(2 Suppl 76):46-9. View

2.
Brand M, Hollaender R, Rosenberg D, Scott M, Hunsche E, Tyndall A . An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database. Clin Exp Rheumatol. 2015; 33(4 Suppl 91):S47-54. View

3.
Sunderkotter C, Herrgott I, Bruckner C, Moinzadeh P, Pfeiffer C, Gerss J . Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol. 2009; 160(4):835-43. DOI: 10.1111/j.1365-2133.2008.09004.x. View

4.
SJOGREN R . Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994; 37(9):1265-82. DOI: 10.1002/art.1780370902. View

5.
Steen V, Powell D, Medsger Jr T . Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988; 31(2):196-203. DOI: 10.1002/art.1780310207. View